Literature DB >> 1879964

Serological discrimination between HTLV-I and HTLV-II antibodies by ELISA using synthetic peptides as antigens.

Y Washitani1, N Kuroda, H Shiraki, Y Nishimura, K Yamaguchi, K Takatsuki, L P Fernando, C T Fang, H Kiyokawa, Y Maeda.   

Abstract

Using the peptides from amino acids 100-130 of the HTLV-I gag protein, 175-199 of the HTLV-I env protein and the corresponding peptides of HTLV-II (amino acids 106 to 135 of the gag protein and 171 to 196 of the env protein), we tested for reactivity against antibodies by enzyme immunoassay in sera from HTLV-I and HTLV-II carriers. The peptides derived from the env proteins have high specificity for antibody binding. The peptide based on amino acids 175-199 of HTLV-I reacted with antibodies in sera from all HTLV-I carriers, and the peptide composed of amino acids 171-196 of HTLV-II reacted with antibodies in sera from all HTLV-II carriers. For the peptides derived from the gag proteins, we observed some cross-reactivity in sera from persons with anti-HTLV-I and anti-HTLV-II, due to antibody binding to the peptide corresponding to 12 amino acids from the C-terminal end of the gag protein. Separate enzyme immunoassays that used the four synthetic peptides as antigens clearly distinguished between serum with antibodies to HTLV-I or HTLV-II in various individuals and excluded false positive results using the particle agglutination assay that used a whole-virus lysate of HTLV-I as antigen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1879964     DOI: 10.1002/ijc.2910490204

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Assessment of a new immunoassay for serological confirmation and discrimination of human T-cell lymphotropic virus infections.

Authors:  M Zrein; J Louwagie; H Boeykens; L Govers; G Hendrickx; F Bosman; E Sablon; C Demarquilly; M Boniface; E Saman
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

2.  Detection of antibodies to hepatitis C virus (HCV) structural proteins in anti-HCV-positive sera by an enzyme-linked immunosorbent assay using synthetic peptides as antigens.

Authors:  C Ishida; K Matsumoto; K Fukada; K Matsushita; H Shiraki; Y Maeda
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

3.  Discrimination between human T-cell lymphotropic virus type I and II (HTLV-I and HTLV-II) infections by using synthetic peptides representing an immunodominant region of the core protein (p19) of HTLV-I and HTLV-II.

Authors:  J Bonis; A Baillou; F Barin; M Verdier; B Janvier; F Denis
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

4.  Truncated MTA-1: a pitfall in ELISA-based immunoassay of HTLV-1 infection.

Authors:  Mohammad Reza Abbaszadegan; Narges Jafarzadeh; Mojtaba Sankian; Abdolreza Varasteh; Mahmoud Mahmoudi; Majid Sadeghizadeh; Fatemeh Khatami; Neema Mehramiz
Journal:  J Biomed Biotechnol       Date:  2008

5.  HTLV-I, HIV-I, and hepatitis B and C viruses in Western Province, Papua New Guinea: a serological survey.

Authors:  K Yamaguchi; T Inaoka; R Ohtsuka; T Akimichi; T Hongo; T Kawabe; M Nakazawa; M Futatsuka; K Takatsuki
Journal:  Jpn J Cancer Res       Date:  1993-07

6.  Southernmost carriers of HTLV-I/II in the world.

Authors:  L Cartier; F Araya; J L Castillo; V Zaninovic; M Hayami; T Miura; J Imai; S Sonoda; H Shiraki; K Miyamoto
Journal:  Jpn J Cancer Res       Date:  1993-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.